GeneCure Biotechnologies is a privately owned biotechnology company specializing in gene therapy technologies aimed at treating both genetic and acquired diseases. Their primary focus is on developing their patented gene transfer technology, known as SimVec, which utilizes a primate lentivirus for safe and efficient gene delivery. This technology has shown promising results in both pre-clinical and clinical trials, particularly in avoiding harmful side effects commonly associated with other gene transfer methods
GeneCure's lead product is HIVAX, a therapeutic vaccine designed for HIV-1 positive patients. The company aims to establish corporate partnerships with pharmaceutical firms to handle large-scale clinical trials, manufacturing, marketing, and distribution of their gene-based therapeutics.
The SimVec technology is notable for its broad host range, stable long-term expression, and high titer production capabilities. It has potential applications in clinical gene transfer, vaccine development, and the production of transgenic animals. This versatility makes it a valuable tool for developing treatments for a variety of diseases, including cancers, infectious diseases, and genetic disorders
Key Features and Applications:
Safety and Efficacy:
GeneCure’s lentiviral vectors have been rigorously tested in animal models and clinical trials, demonstrating a strong safety profile with no harmful side effects. The use of lentiviral vectors addresses the common concerns of generating replication-competent retroviruses (RCR), ensuring that the gene transfer technology is safe for human applications (GeneCure).
Pre-existing Immunity:
One major benefit of GeneCure’s technology is its lack of pre-existing immunity in humans. Since the simian immunodeficiency virus (SIV) is not a human pathogen, patients do not have pre-existing immunity against it. This allows for efficient gene transfer without the immune system targeting the vector, which is a common issue with other viral vectors like adenoviruses (GeneCure).
Broad Host Range:
The SimVec technology can infect a wide variety of cell types, both mammalian and non-mammalian, due to the incorporation of the vesicular stomatitis virus G protein (VSV-G) into the viral envelope. This broad host range expands the potential applications of the technology across different species and cell types (GeneCure).
High Titer Production:
GeneCure's technology allows for the production of lentiviral particles at high titers, essential for clinical applications requiring large quantities of vectors. This high titer production ensures that the technology can meet the demands of large-scale clinical trials and therapeutic applications (GeneCure).
Clinical Gene Therapy
Treating genetic, acquired diseases (e.g., cancer), and infectious diseases by delivering therapeutic genes to human primary cells.
Vaccine Development
Creating both preventive and therapeutic vaccines for diseases like HIV, SARS, malaria, tuberculosis, hepatitis, influenza, and Ebola.
Support Team
We have a support team that will do everything to answer you as quickly as the voice assistants.